VIDEO: 'Practice-changing studies' from the 2024 ASCO Gastrointestinal Symposium
Click Here to Manage Email Alerts
In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.
“There are some really exciting data that came out of the meeting, including potentially practice-changing studies,” Schroff said.
Among the highlights were the results of the SKYSCRAPER-08 study, a phase 3, randomized, double-blind, placebo-controlled study of first-line tiragolumab (Genentech/Roche) plus atezolizumab (Tecentriq, Genentech/Roche) and chemotherapy in patients with esophageal squamous cell carcinoma; and the MATTERHORN study of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel, with or without durvalumab (Imfinzi, AstraZeneca), in resectable gastric/ gastroesophageal junction cancer.
"I think it's really demonstrating that we can start to think differently about combination therapies and perioperative approaches in the setting of upper GI malignancies," Shroff said.
In addition, Shroff discusses data from two positive studies in the hepato-pancreato-biliary space, including results from the NETTER-2 and EMERALD-1 studies.
References:
- Hsu CH, et al. Abstract 245. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
- Janjigian Y, et al. Abstract LBA246. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
- Lencioni R, et al. Abstract LBA432. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
- Singh S, et al. Abstract LBA588. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts